Last reviewed · How we verify
NCT06672523
A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion
Phase 1 trial testing BMS-986504 in Advanced Solid Tumors With Homozygous MTAP Deletion in 8 participants. Currently enrolling.
20 April 2026
Quick facts
| Lead sponsor | Bristol-Myers Squibb |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 8 |
| Start date | 24 March 2025 |
| Primary completion | 20 April 2026 |
| Estimated completion | 20 April 2026 |
| Sites | 3 locations across Spain, Hungary |
Drugs / interventions tested
- BMS-986504 — full drug profile →
- [14C]-BMS-986504 — full drug profile →
Conditions studied
- Advanced Solid Tumors With Homozygous MTAP Deletion — all drugs for Advanced Solid Tumors With Homozygous MTAP Deletion →
Sponsor
Bristol-Myers Squibb — full company profile →
Who can join
18 and older, any sex, with Advanced Solid Tumors With Homozygous MTAP Deletion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the mass balance, metabolism, elimination, and drug levels of \[14C\]-BMS-986504 (MRTX1719) in participants with advanced solid tumors with homozygous methylthioadenosine phosphorylase deletion.
Publications & conference data
6 peer-reviewed publications reference this trial (live from Europe PMC):
-
Arginine methylation in cancer: mechanisms and therapeutic implications.
Xu Y, Wu Q, Zhang Y, Gu Y, et al · · 2025 · cited 2× · PMID 41204384 · DOI 10.1186/s40364-025-00860-5 -
Cracking PRMT5: Mechanistic insights, clinical advances, and AI-driven strategies.
Alipourgivi F, Su J, Lu T. · · 2025 · cited 2× · PMID 41072789 · DOI 10.1016/j.canlet.2025.218075 -
Synthetic lethality in cancer therapy: Mechanisms, models and clinical translation for overcoming therapeutic resistance.
Li J, Zhang L, Shang Y, Liu J, et al · · 2026 · cited 1× · PMID 41537447 · DOI 10.1002/ctm2.70586 -
Protein arginine methyltransferases in cancer: mechanisms, functions, and therapeutic opportunities.
Jeong Y, Cho Y, Kim YK. · · 2026 · PMID 41928257 · DOI 10.1186/s12929-026-01240-3 -
<i>MTAP</i> Deletion as a Therapeutic Vulnerability in Cancer: From Molecular Mechanism to Clinical Targeting.
Krawczyk P, Wojas-Krawczyk K. · · 2025 · PMID 41465382 · DOI 10.3390/ijms262411956 -
Arginine methylation regulates Ewing sarcoma cell viability in a <i>EWSR1::FLI1</i> dependent manner and provides a therapeutic opportunity.
Ward CM, Brockwell C, McNee GS, Orton E, et al · · 2025 · PMID 40823091 · DOI 10.3389/fonc.2025.1538208
Verify or expand the search:
- PubMed search for NCT06672523
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of BMS-986504
Trials testing the same drug.
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
- NCT07283705 — A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer · Phase 2 · recruiting
- NCT07063745 — A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab a · Phase 2, PHASE3 · recruiting
- NCT07076121 — A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-p · Phase 2, PHASE3 · recruiting
- NCT07077434 — A Study to Assess Safety, Tolerability and Drug Levels of BMS-986504 in Participants With Advanced Solid Tumors · Phase 1 · recruiting
Other Bristol-Myers Squibb trials
Trials by the same sponsor.
- NCT07441408 — Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis · Phase 3 · not yet recruiting
- NCT07459543 — A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unre · Phase 4 · not yet recruiting
- NCT07285798 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder · Phase 3 · not yet recruiting
- NCT07284745 — A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism · Phase 3 · not yet recruiting
- NCT07492680 — A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic S · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06672523 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Bristol-Myers Squibb
- Last refreshed: 9 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06672523.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing